Ausgabe 2/2011
Inhalt (32 Artikel)
UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer
Yu Sunakawa, Wataru Ichikawa, Ken-ichi Fujita, Fumio Nagashima, Hiroo Ishida, Keishi Yamashita, Keiko Mizuno, Keisuke Miwa, Kaori Kawara, Yuko Akiyama, Kazuhiro Araki, Wataru Yamamoto, Toshimichi Miya, Masaru Narabayashi, Yuichi Ando, Takashi Hirose, Shigehira Saji, Yasutsuna Sasaki
Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability
Kyu-pyo Kim, Min-Hee Ryu, Changhoon Yoo, Baek-Yeol Ryoo, Dae Ro Choi, Heung Moon Chang, Jae-Lyun Lee, Mo Youl Beck, Tae Won Kim, Yoon-Koo Kang
A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors
Matthew H. Kulke, Jennifer A. Chan, Jeffrey A. Meyerhardt, Andrew X. Zhu, Thomas A. Abrams, Lawrence S. Blaszkowsky, Eileen Regan, Carolyn Sidor, Charles S. Fuchs
Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy
Kohei Shitara, Keitaro Matsuo, Isao Oze, Ayako Mizota, Chihiro Kondo, Motoo Nomura, Tomoya Yokota, Daisuke Takahari, Takashi Ura, Kei Muro
Is there any impact of plasma M30 and M65 levels on progression-free survival of patients with advanced gastric cancer?
Ahmet Bilici, Bala Basak Oven Ustaalioglu, Serif Ercan, Asuman Orcun, Mesut Seker, Taflan Salepci, Mahmut Gumus
Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX
Myung Hee Chang, In Kyu Lee, Yoon Si, Kyu Sang Lee, In-Sook Woo, Jae Ho Byun
The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention
Susan K. Peirce, Harry W. Findley, Chengyu Prince, Anindya Dasgupta, Todd Cooper, Donald L. Durden
Second platinum therapy in patients with uterine cervical cancer previously treated with platinum chemotherapy
Maki Tanioka, Noriyuki Katsumata, Kan Yonemori, Tsutomu Kouno, Chikako Shimizu, Kenji Tamura, Masashi Ando, Yasuhiro Fujiwara
Experiment on enhancing antitumor effect of intravenous epirubicin hydrochloride by acoustic cavitation in situ combined with phospholipid-based microbubbles
Cui-Tao Lu, Ying-Zheng Zhao, Yan Wu, Xin-Qiao Tian, Wen-Feng Li, Pin-Tong Huang, Xiao-Kun Li, Chang-Zheng Sun, Lu Zhang
Anticancer effect of (E)-2-hydroxy-3′,4,5′-trimethoxystilbene on breast cancer cells by mitochondrial depolarization
Yee Soo Chae, Jong Gwang Kim, Hyun Jun Jung, Jung Dug Yang, Jin Hyang Jung, Sarah E. Aiyar, Sanghee Kim, Hoyong Park
Conjugation of chlorin p 6 to histamine enhances its cellular uptake and phototoxicity in oral cancer cells
Arpana Parihar, Alok Dube, P. K. Gupta
Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors
Yuan Yuan, Deirdre J. Cohen, Erica Love, Michelle Yaw, Benjamin Levinson, Steven J. Nicol, Howard S. Hochster
Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer
Allyson J. Ocean, Paul Christos, Joseph A. Sparano, Dan Matulich, Andreas Kaubish, Abby Siegel, Max Sung, Maureen M. Ward, Nancy Hamel, Igor Espinoza-Delgado, Yun Yen, Maureen E. Lane
The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models
Young-Soon Na, Kyung-Ah Jung, Seung-Mi Kim, Yong Sang Hong, Min-Hee Ryu, Se Jin Jang, Dae Hyuk Moon, Dong-Hyung Cho, Jin Cheon Kim, Jung Shin Lee, Tae Won Kim
Lack of in vivo cross-resistance with 4′-thio-ara-C against drug-resistant murine P388 and L1210 leukemias
William R. Waud, Karen S. Gilbert, John A. Secrist III
Antitumor agent PX-12 inhibits HIF-1α protein levels through an Nrf2/PMF-1-mediated increase in spermidine/spermine acetyl transferase
Yon Hui Kim, Amy Coon, Amanda F. Baker, Garth Powis
A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer
Athanasios Kotsakis, Sophia Agelaki, Nikolaos Vardakis, George Stathopoulos, Lambros Vamvakas, Antonia Kalykaki, Nikolaos Kentepozidis, Emmanouel Kontopodis, Georgia Sfakiotaki, Dimitris Mavroudis, Vassilis Georgoulias
Clinical benefit of early phase clinical trial participation for advanced sarcoma patients
Robin L. Jones, David Olmos, Khin Thway, Cyril Fisher, Nina Tunariu, Sophie Postel-Vinay, Michelle Scurr, Johann de Bono, Stan B. Kaye, Ian R. Judson
The uptake of paclitaxel and docetaxel into ex vivo porcine bladder tissue from polymeric micelle formulations
Antonia Tsallas, John Jackson, Helen Burt
Improved antiangiogenic and antitumour activity of the combination of the natural flavonoid fisetin and cyclophosphamide in Lewis lung carcinoma-bearing mice
Yasmine S. Touil, Johanne Seguin, Daniel Scherman, Guy G. Chabot
Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer
Eleni Andreopoulou, Thomas Chen, Leonard Liebes, John Curtin, Stephanie Blank, Robert Wallach, Howard Hochster, Franco Muggia
Prediction of human pharmacokinetics and tissue distribution of apicidin, a potent histone deacetylase inhibitor, by physiologically based pharmacokinetic modeling
Beom Soo Shin, Jürgen B. Bulitta, Joseph P. Balthasar, Minki Kim, Yohan Choi, Sun Dong Yoo
Cytotoxic responses to N-(4-hydroxyphenyl)retinamide in human pancreatic cancer cells
Maria C. Messner, Myles C. Cabot
Antitumor effects of (S)-HDAC42, a phenylbutyrate-derived histone deacetylase inhibitor, in multiple myeloma cells
Li-Yuan Bai, Hany A. Omar, Chang-Fang Chiu, Zeng-Pang Chi, Jing-Lan Hu, Jing-Ru Weng
The therapeutic efficacy of S-1 against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice
Trung The Van, Masaki Hanibuchi, Soji Kakiuchi, Seidai Sato, Takuya Kuramoto, Hisatsugu Goto, Atsushi Mitsuhashi, Yasuhiko Nishioka, Shin-ichi Akiyama, Saburo Sone
Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors
M. Tanioka, H. Nokihara, N. Yamamoto, Y. Yamada, K. Yamada, Y. Goto, T. Fujimoto, R. Sekiguchi, K. Uenaka, S. Callies, T. Tamura
Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination
Lee Jia, Gregory S. Gorman, Lori U. Coward, Patricia E. Noker, David McCormick, Thomas L. Horn, J. Brooks Harder, Miguel Muzzio, Bellur Prabhakar, Balaji Ganesh, Tapas K. Das Gupta, Craig W. Beattie
Determination of 5-fluorouracil and dihydrofluorouracil levels by using a liquid chromatography–tandem mass spectrometry method for evaluation of dihydropyrimidine dehydrogenase enzyme activity
Muhittin A. Serdar, Erdim Sertoğlu, Metin Uyanık, Serkan Tapan, Okhan Akın, Murat Cihan
Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats
Jong-Mu Sun, Mi Hyun Nam, Jae Yong Chung, Bohee Im, Soo-Youn Lee, Youn-Lim Suh, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma
Ghassan K. Abou-Alfa, Stephan L. Chan, Chia-Chi Lin, E. Gabriela Chiorean, Randall F. Holcombe, Mary F. Mulcahy, William D. Carter, Kashyap Patel, William R. Wilson, Teresa J. Melink, John C. Gutheil, Chao-Jung Tsao
Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer
Peter D. Boasberg, Charles H. Redfern, Gregory A. Daniels, David Bodkin, Chris R. Garrett, Alejandro D. Ricart